Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Katja Sladko"'
Autor:
Gunther Spohn, Christian Schori, Iris Keller, Katja Sladko, Christina Sina, Reto Guler, Katrin Schwarz, Pål Johansen, Gary T Jennings, Martin F Bachmann
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 1, Iss C (2014)
Neutralization of the inflammatory cytokine interleukin-1β (IL-1β) is a promising new strategy to prevent the β-cell destruction, which leads to type 2 diabetes. Here, we describe the preclinical development of a therapeutic vaccine against IL-1β
Externí odkaz:
https://doaj.org/article/56bc39e0b1774043a0401a3455439423
Autor:
Alma Fulurija, Thomas A Lutz, Katja Sladko, Melania Osto, Peter Y Wielinga, Martin F Bachmann, Philippe Saudan
Publikováno v:
PLoS ONE, Vol 3, Iss 9, p e3163 (2008)
BACKGROUND: According to the WHO, more than 1 billion people worldwide are overweight and at risk of developing chronic illnesses, including cardiovascular disease, type 2 diabetes, hypertension and stroke. Current therapies show limited efficacy and
Externí odkaz:
https://doaj.org/article/a38150476f32489a87dfbeb36dfd1855
Autor:
Kirsten Roubicek, Frank Wagner, Vera Nief, Charlotte Schellekens, Katja Sladko, Manfred Rettenbacher, Patrice M. Ambühl, Juerg Nussberger, Alma Fulurija, Robert Sabat, Martin F. Bachmann, Thomas Pfister, Philipp L. Müller, Patrik Maurer, Gary T. Jennings, Alain Tissot, Hans-Dieter Volk
Publikováno v:
Journal of Hypertension. 25:63-72
BACKGROUND: Despite the availability of efficacious drugs, the success of treating hypertension is limited by patients' inconsistent drug intake. Immunization against angiotensin II may offer a valuable alternative to conventional drugs for the treat
Autor:
Thomas A. Lutz, Alma Fulurija, Philippe Saudan, Martin F. Bachmann, Melania Osto, Katja Sladko, Peter Y. Wielinga
Publikováno v:
PLoS ONE
PLoS ONE, Vol 3, Iss 9, p e3163 (2008)
PLoS ONE, Vol 3, Iss 9, p e3163 (2008)
Background According to the WHO, more than 1 billion people worldwide are overweight and at risk of developing chronic illnesses, including cardiovascular disease, type 2 diabetes, hypertension and stroke. Current therapies show limited efficacy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e8007b0bde413364fd2fbce9641fe7e
https://www.zora.uzh.ch/id/eprint/4573/
https://www.zora.uzh.ch/id/eprint/4573/
Autor:
Alma Fulurija, Frank Hennecke, Katja Sladko, Gabriel Schnetzler, Gary T. Jennings, Bettina M. Prinz Vavricka, Thomas M. Kündig, Martin F. Bachmann, Gabriela Senti, Charles Wolf
Publikováno v:
The Journal of allergy and clinical immunology. 117(6)
BACKGROUND: In mice, highly repetitive antigens, such as those present on bacterial or viral surfaces, efficiently cross-link B-cell receptors and therefore induce strong IgG responses. In this study we covalently coupled a synthetic 16-amino-acid se
Autor:
Christina Sina, Pål Johansen, Katrin Schwarz, Reto Guler, Katja Sladko, Gunther Spohn, Christian Schori, Iris Keller, Martin F. Bachmann, Gary T. Jennings
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 1, Iss C (2014)
Mol Ther Methods Clin Dev
Molecular Therapy: Methods & Clinical Development, Vol 1, Iss C (2014)
Mol Ther Methods Clin Dev
Neutralization of the inflammatory cytokine interleukin-1β (IL-1β) is a promising new strategy to prevent the β-cell destruction, which leads to type 2 diabetes. Here, we describe the preclinical development of a therapeutic vaccine against IL-1β